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Introduction {#sec001}
============

Isoniazid (INH) is broadly used in the therapy of tuberculosis. INH, when used in combination with other drugs, is often accompanied with outcome of acute as well as chronic liver disease \[[@pone.0236992.ref001]--[@pone.0236992.ref004]\]. INH frequently causes drug induced liver injury (DILI) not only in India but also in many developing countries where there is high prevalence of tuberculosis. High mortality in anti tubercular drug (ATD) related acute liver failure is observed and many times, the patients require liver transplantation \[[@pone.0236992.ref005]\]. Moreover, chronic liver injury is reported from patients treated with INH from developing as well as developed countries \[[@pone.0236992.ref002], [@pone.0236992.ref004]\]. However, the mechanism is not yet known. Within the liver, hepatocyte is the primary site for INH metabolism. During metabolism, the conversion of INH to acetylisoniazid is mediated by N-acetyltransferase 2 (NAT2), which in turn is hydrolysed to acetylhydrazine \[[@pone.0236992.ref006]\]. Acetylhydrazine is further oxidized by cytochrome P450 2E1 (CYP2E1) to generate potential toxic metabolites. Hepatotoxicity triggered by INH is thought to be mediated partly by the activity of CYP2E1. CYP2E1 was found to be involved in generating oxidative stress in INH induced liver injury \[[@pone.0236992.ref007]\]. Within the liver, CYP2E1 content is highest in hepatocytes. As a microsomal enzyme, CYP2E1 takes a pivotal role in dealing with free radicles and thus plays an important role in hepatocyte injury related to oxidative stress. Liver scarring is a common outcome of chronic liver injury \[[@pone.0236992.ref008]\]. During liver injury caused by many etiologies, quiescent hepatic stellate cells (HSCs) transform into fibrogenic myofibroblasts \[[@pone.0236992.ref009]\]. Stimulus that causes activation of HSC usually comes from damaged hepatocytes as well as from Kupffer cells and endothelial cells \[[@pone.0236992.ref010]\]. But in chronic liver disease related to INH treatment, we have no information whether INH directly involves in proliferation and activation of HSC resulting collagen synthesis or these effects are derived from paracrine signals of INH induced damaged hepatocytes. This could have implications in finding out the subcellular pathways which may possibly progress to biomarkers generation and to identify targets in drug development. In this paper, we examined whether INH directly cause activation of HSC and increase collagen formation using LX2 cells, an immortalized human hepatic stellate cell line.

Materials and methods {#sec002}
=====================

Cell line and culture {#sec003}
---------------------

We used LX2 cell line, an immortalized human hepatic stellate cells for this study. LX2 cell line was established in 2005 by Xu et al \[[@pone.0236992.ref011]\] at Mount Sinai School of Medicine, New York, USA. The LX2 cell line was obtained from Scott L Friedman (Mount Sinai School of Medicine, New York, USA). Dulbecco's modified Eagles medium \[DMEM; (D5921; Sigma-Aldrich, St. Louis, MO)\] was used to culture LX2 cells at 37°C in an atmosphere of 5% CO~2~. The medium contained 2% fetal Bovine serum \[FBS (10270106; Gibco, Thermo Fisher, USA), 1mmol/L L-glutamine (G7513; Sigma-Aldrich, St. Louis, MO) and 100 IU/ml penicillin-streptomycin (P4458; Sigma-Aldrich, St. Louis, MO).

Treatment of cells {#sec004}
------------------

We treated LX2 cells at passage 4 to 6 with 5 μM INH when the cells were 60% confluent. Phosphate buffered saline \[PBS(I3377; Sigma-Aldrich, St. Louis, MO) (P5368; Sigma-Aldrich, St. Louis, MO)\] was used for dilution of INH. LX2 cells were exposed to either INH or PBS alone for 24 to 72 hours. In some experiments, we added antioxidants such as N-Acetyl-L-Cysteine \[NAC (A7250; Sigma-Aldrich, St. Louis, MO)\], TEMPOL (176141;Sigma-Aldrich,St. Louis,MO) and different inhibitors like diphenyleneiodonium \[DPI (D2926; Sigma Aldrich, St. Louis, MO)\], a NADPH oxidase (NOX) inhibitor and chlormethiazole, a CYP2E1 inhibitor \[CMZ (C1240; Sigma Aldrich, St. Louis, MO)\] in the culture medium 3 hours prior to INH treatment.

Induction of CYP2E1 in LX2 cells {#sec005}
--------------------------------

To examine the influence of CYP2E1 in INH mediated HSC activation, in separate sets of experiments; we added 50 μM pyrazole \[PY (P56607; Sigma-Aldrich, St. Louis, MO\] in culture medium 3 hours prior to addition of INH.

Biochemical assays {#sec006}
------------------

### A) GSH assay {#sec007}

Prior any treatment, cells (1x10^6^) were seeded and incubated in DMEM media overnight. Following INH treatment for different time periods, cells were washed with PBS followed by trypsinization and centrifugation at 2000 rpm for 2 minutes. 400 μl of 10% trichloroacetic acid \[TCA (T6399; Sigma Aldrich, St. Louis, MO)\] was added to the cell pellet so that cellular reduced glutathione (GSH) could be extracted. At 13,000 g for 1 min, the cell suspension was centrifuged to eliminate denatured proteins. The supernatant was used to determine GSH by the enzymatic method of Tietze \[[@pone.0236992.ref012]\]. Briefly, 250 μl of cell supernatant was incubated with 1.25 ml of 0.1 M sodium phosphate buffer containing DTNB \[5,5'-dithiobis-(2-nitrobenzoic acid; D8130; Sigma Aldrich, St. Louis, MO\] and then absorbance of samples was recorded at 412 nm.

### B) Lipid peroxidation analysis {#sec008}

Measurement of lipid peroxidation was carried out by a previously described method \[[@pone.0236992.ref013]\]. Briefly, 1X10^5^ cells were plated in six well plates prior to treatment with INH. Following overnight culture, LX2 cells were treated with INH for 24 to 72 hours. After treatment, the cells were trypsinized and suspended in PBS. The suspended cells were subjected to sonication followed by centrifugation of the cell lysate at 14000 rpm for 20 minutes. Protein was determined from the supernatant using Bradford method. To 100 μl of cell supernatant, 200 μl of 10% TCA and 400 μl of 0.67% thiobarbituric acid (TBA; T5500; Sigma Aldrich, St. Louis, MO) were added in a boiling water bath for 45 min. After being cooled in an ice bath, equal volume of tertiary butanol (19460; Sigma Aldrich, St. Louis, MO) was added to the samples followed by centrifugation at 10000 rpm for 10 min. The absorbance of the resulting supernatant was read at 532 nm to determine formation of TBA reactive components.

### C) Protein content {#sec009}

RIPA buffer (9806; Cell Signaling Technology, U.S.A) was used to prepare whole cell lysate for estimation of proteins along with protease inhibitors cocktail (11836153001; Roche Diagnostics, Mannheim, Germany). Centrifugation of the lysate was carried out at 14,000×g for 20min at 4°C. Using Bradford reagent (6916; Sigma Aldrich, St. Louis, MO) the protein content of the supernatant was measured \[[@pone.0236992.ref014]\]. Briefly, in 1.5 ml of Bradford reagent, 5 μl of cell supernatant was mixed well and was allowed to stand for 20 minutes in dark at room temperature. The absorbance was recorded at 595 nm spectrophotometrically.

### D) CYP2E1 activity {#sec010}

Evaluation of CYP2E1 activity was determined by a previously described method \[[@pone.0236992.ref015]\]. Cells were harvested by trypsinization and subjected to sonication. Using differential centrifugation method, microsomes were prepared. CYP2E1 activity was assessed using 100 μg microsomal protein incubated with 0.4 mM paranitrophenol \[PNP (1048; Sigma Aldrich, St. Louis, MO)\] and 1 mM reduced nicotinamide adenine dinucleotide phosphate \[NADPH (N9660; Sigma Aldrich,St.Louis, MO)\] at 37º for 60 minutes. Following incubation, 20% TCA was added and samples were placed on ice. Just before reading, 2M sodium hydroxide (NaOH) was added. The enzymatic product was assessed at 520 nm within a few minutes by a spectrophotometer and activity of CYP2E1 was calculated.

### E) Catalase activity {#sec011}

Using the protocol of Beers and Sizer \[[@pone.0236992.ref016]\], catalase activity assay was carried out spectrophotometrically. Briefly, in 1.9ml of 0.05M sodium phosphate buffer (pH 7) containing 0.059M hydrogen peroxide (H~2~O~2;~ 8.22287; Sigma Aldrich, St. Louis, MO), 50 μg protein was added. The reaction was initiated by adding 1ml H~2~O~2~ solution. The change in absorbance was read at 240 nm for 3 minutes and the specific activity was calculated.

### F) Glutathione peroxidase (GPx) activity {#sec012}

GPx activity was measured according to the method of Paglia and Valentine \[[@pone.0236992.ref017]\]. In brief, the reaction mixture consists of cell supernatant containing 50 μg of protein, 1% sodium azide (S2002; Sigma Aldrich, St. Louis, MO), 0.15 M reduced GSH (G6013; Sigma Aldrich, St. Louis, MO), yeast glutathione reductase (G3664; Sigma Aldrich, St. Louis, MO), 5mM EDTA (E6758; Sigma Aldrich, St. Louis, MO) and 0.89 mM NADPH in 0.1M sodium phosphate buffer. The reaction was initiated by the addition of 0.72 mM H~2~O~2~ (8.22287; Sigma Aldrich, St. Louis, MO). The absorbance of the samples was measured at 340 nm using a spectrophotometer. The change in absorbance was recorded at 1 min interval at 340 nm for 5 minutes.

### G) NADPH oxidase (NOX) activity {#sec013}

NOX activity was carried out as previously described \[[@pone.0236992.ref018]\]. The assay system comprises of cell supernatant along with 250 μmol/l NADPH with or without 10 μmol/l DPI (D2926; Sigma Aldrich, St. Louis, MO), 30 min before the assay and the rate of NADPH consumption was examined by the decrease in absorbance at 340 nm for 10 min. NOX activity was calculated using the absorption extinction coefficient of the amount of NADPH consumed which was 6.22 mM^-1^ cm-^1^.

DCF staining for ROS {#sec014}
--------------------

Assessment of intracellular ROS was done with the help of fluorescent probe 2',7'-dichlorofluorescin diacetate (DCF-DA; D6883) obtained from Sigma-Aldrich, St. Louis, MO, to the cultured LX2 cells at various hours of INH treatment using flow cytometer (BD FACS Calibur, BD Bioscience, Pharmingen, USA) using FL1 channel to detect DCF fluorescence \[[@pone.0236992.ref019]\]. In brief, 30 min before the end of treatment programme with or without INH, 5 μM DCF-DA was added to LX2 cells in serum free DMEM in dark for 30 min at 37°C. Following staining, the cells were subjected to trypsinization after washing and finally resuspended in PBS. DCF fluorescence intensity was measured using flow cytometry from 10,000 cells by Cell Quest software.

mRNA expression using quantitative real time polymerase chain reaction {#sec015}
----------------------------------------------------------------------

From LX2 cells RNA was extracted utilizing trizol reagent (15596026; Ambion, Life technologies, USA) according to the guidelines of the manufacturer. RNA was converted to cDNA with the help of random hexamers and reverse transcriptase as per recommendation by the commercial kit (K1622; Thermo Scientific, UK). The following primers were used for Quantitative real-time Polymerase Chain Reaction (qRT-PCR): glyceraldehydes 3-phosphate dehydrogenase (GAPDH): Forward: `5’-AGGGCTGCTTTTAACTCTGGT-3’`; Reverse: `5’-CCCCACTTGATTTTGGAGGGA-3’`; alpha smooth muscle actin (α-SMA): Forward: `5’-CTGTTCCAGCCATCCTTCAT-3’`; Reverse: `5’-CGGCTTCATCGTATTCCTGT-3’`; Collagen1A1 (COL1A1): Forward: `5’-GAACATCACCTACCACTGCA-3’`; Reverse: `5’-GTTGGGATGGAGGGAGTTTA-3’`; transforming growth factor beta (TGF-β): Forward: `5’-GCCCTGGACACCAACTATTGC-3’`;Reverse:`5’GCTGCACTTGCAGGAGCGCAC-3’`; tissue inhibitor of matrix metalloporoteinase (TIMP-1): Forward: `5’-AGACGGCCTTCTGCAATTCC-3’`; Reverse: `5’-GAAGCCCTTTTCAGAGCCTT-3’`; Matrix metalloprotienase (MMP-2): Forward: `5’- TCGCCCATCATCAAGTTCCC-3’`; Reverse: `5’- TCTGGGGCAGTCCAAAGAAC-3’`; Matrix metalloprotienase (MMP-9): Forward:`5’-GTGATTGACGACGCCTTTGC-3’`; Reverse:`5’GGACCACAACTCGTCATCGT-3’`. From cDNA, qRT-PCR was executed using StepOne Plus thermocycler (ABI), primer sets and SYBR® green PCR master mix (436759; Applied Biosystems, UK) as per instructions provided by the manufacturer. GAPDH was used as a housekeeping gene for expression of genes.

Proliferation assay {#sec016}
-------------------

MTT \[3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide\] assay was used to detect proliferation of LX2 cells according to manufacturer's instructions using the Vybrant® MTT Cell Proliferation Assay Kit (V13154; Molecular probes, Life technologies, USA). In brief, in a 96 well microplate, 1×10^4^ LX2 cells/well were seeded and cultured in DMEM media for 24 hours. Following 72 hours exposure to 5 μM INH in presence or absence of 50 μM PY, fresh media was added to which 10 μl of 12 mM MTT solution was added to medium in each well of the 96-well plates. The plates were incubated at 37ºC for 4 hours. To 25 μl media, 50 μl DMSO (SRL, India) was added to each well and mixed well. At 540 nm optical density was measured using a microplate reader (Molecular Devices; USA).

Sircol collagen assay {#sec017}
---------------------

Sircol^TM^ soluble collagen assay kit (S1000; Biocolor, UK) was used to determine total soluble collagen content as per instructions provided by the manufacturer. In brief, at the end of different time periods, media from both control and experimental groups were kept for 24 hours at 4ºC. Following centrifugation, 100 μl of each supernatant was incubated with 1 ml of Sircol dye reagent and mixed for 30 minutes. Samples were again centrifuged and to the resulting pellet 1 ml of the alkali reagent was added and reading was taken at 540 nm with a spectrophotometer.

Western blotting {#sec018}
----------------

Following denaturation in sample loading buffer, forty micrograms protein was separated on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Following transfer onto Polyvinylidene fluoride (PVDF) membranes (IPVH00010, Merck millipore, India), the membrane was incubated with 5% skimmed milk (5751D; Loba chemie, India) which functions as a blocking agent. The blots were further probed with the following primary antibodies: mouse monoclonal α-SMA (sc-53015; Santa Cruz Biotechnology, Santa Cruz, USA) in a dilution of 1:300, mouse monoclonal beta actin (sc-47778; Santa Cruz Biotechnology, Santa Cruz, USA) in a dilution of 1:1000, mouse monoclonal collagen 1A1 (sc-80760; Santa Cruz Biotechnology, Santa Cruz, USA) in a dilution of 1:300, mouse monoclonal NOX1 (sc-25545; Santa Cruz Biotechnology, Santa Cruz, USA) in a dilution of 1:300, mouse monoclonal NOX2 (sc-74514; Santa Cruz Biotechnology, Santa Cruz, USA) in a dilution of 1:300, rabbit polyclonal CYP2E1 (ab53945; Abcam, USA) in a dilution of 1:300 and mouse monoclonal NOX4 (sc-518092; Santa Cruz Biotechnology, Santa Cruz, USA) in a dilution of 1:300. As a secondary antibody, we used anti mouse IgG (32430; Thermo Scientific, USA) and anti rabbit IgG (32460; Thermo Scientific, USA) in a dilution of 1:1000 conjugated with Horseradish peroxidise (HRP). Chemiluminescent detection method was used to develop blots using the Supersignal west Pico plus chemiluminescent reagent (34580; Thermo Scientific, U.S.A)

Statistical analysis {#sec019}
--------------------

All experiments were conducted minimum five times. We presented the data as means ± standard deviation (SD). To critically analyse statistical differences between groups, Student's t test was performed. A *p* value less than 0.05 was considered statistically significant.

Results {#sec020}
=======

CYP2E1 and NOX activities in LX2 cells during INH exposure {#sec021}
----------------------------------------------------------

CYP2E1 plays the most vital drug metabolizing enzymes including INH. CYP2E1 produces huge amount of ROS \[[@pone.0236992.ref020]\]. Based on a previous study, ATD induced CYP2E1 expression resulted in apoptotic death of the hepatocytes in experimental model. \[[@pone.0236992.ref007]\]. However, there is no information available to clarify whether CYP2E1 is induced by INH in the HSCs provoking development of cellular oxidative stress and fibrogenesis. We therefore measured CYP2E1 activity in LX2 cells. At 0 hour, CYP2E1 activity in LX2 cells was low (14.96 ±0.69 pmol/min/mg of microsomal protein) which remain unchanged during 72 hours in control experiments (without INH treatment) ([Fig 1A](#pone.0236992.g001){ref-type="fig"}). Addition of INH (5 μM) in the culture medium showed slow but progressive elevation of CYP2E1 activity in LX2 cells till 72 hours of culture ([Fig 1A](#pone.0236992.g001){ref-type="fig"}). This finding was further confirmed by western blot ([Fig 1B](#pone.0236992.g001){ref-type="fig"}). NOX activity in LX2 cells was elevated during INH treatment which was parallel with the increase of CYP2E1 activity ([Fig 1C](#pone.0236992.g001){ref-type="fig"}). NOX is composed of many protein molecules and produce ROS not only in phagocytic cells but also in non-phagocytic cells. Further, in the liver, NOX has significant involvement during fibrogenesis. Hence, expression of both phagocytic (NOX2) and non-phagocytic (NOX1 and NOX4) isoforms of NOX was estimated in LX2 cells during INH exposure. While both control and INH treated LX2 cells exhibited expression of NOX1 protein, however the difference in expression of NOX1 between control and INH treated group at different time points was found to be insignificant ([Fig 1D](#pone.0236992.g001){ref-type="fig"}). Expression of NOX4 protein was not found in control as well as in INH treated LX2 cells ([Fig 1D](#pone.0236992.g001){ref-type="fig"}). But marked expression of NOX2 protein was observed only at 72 hours of INH treatment in LX2 cells.

![Activities of CYP2E1 and NOX and their protein expression in LX2 cells at different hours of INH exposure.\
LX2 cells were incubated with or without INH for 24, 48 and 72 hours (h). Further, data at 0 hour before INH treatment was also depicted in the figure. LX2 cells without INH treatment served as control. (A) Determination of CYP2E1 activity (pmol *p-*nitrocatechol/min/mg of protein) was performed. \*p\<0.01 compared to 48 h control cells; \*\*p\<0.01 compared to 24 h INH treated group and \#p\<0.001 compared to 72 h control cells \[n = 6\]. (B) Western blot of CYP2E1 protein in the cell lysates in response to INH treatment was carried out at various intervals. β-actin was used as in house control \[n = 5\]. (C) NOX activity \[n = 6\] and (D) protein expression of NOX1, NOX2 and NOX4 in the cell lysates with INH treatment (T) and without INH treatment (C) at various time periods were detected by Western blotting \[n = 5\]. β-actin was used as in house control. \*p\<0.01 compared to 48 h control cells; \*\*p\<0.001 compared to 72 h control cells and \#p\<0.01 compared to 48 h INH treated group.](pone.0236992.g001){#pone.0236992.g001}

Intracellular ROS in LX2 cells during INH treatment {#sec022}
---------------------------------------------------

Intracellular ROS produced during the P450 catalytic cycle contributes to oxidative stress \[[@pone.0236992.ref021]\]. So we examined the intracellular ROS formation in LX2 cells during INH treatment. DCF fluorescence is a surrogate marker of intracellular hydrogen peroxide (H~2~O~2~) generation. Using flow cytometer, the percentage of LX2 cells producing ROS at different hours of INH treatment was measured. At basal level, 3% of the LX2 cells were found to generate intracellular ROS. The percentage of LX2 cells producing intracellular ROS was increased with duration of INH treatment ([Fig 2A](#pone.0236992.g002){ref-type="fig"}). At different hours of INH exposure, we further measured intracellular ROS level in LX2 cells by fluorescence spectrophotometry. At basal level, the DCF fluorescence, was found to be 2.0 ± 0.23 AFU/ 10^6^ cells. The ROS content in LX2 cells after 72 hours of INH treatment was 12 ± 1.25 AFU/10^6^ cells (p \< 0.05) \[[Fig 2B](#pone.0236992.g002){ref-type="fig"}\]. Pretreatment of LX2 cells with anti-oxidants (NAC, Tempol), NOX inhibitor DPI and CYP2E1 inhibitor CMZ prior to INH treatment significantly reduced intracellular ROS formation in response to INH treatment as depicted in [Fig 2C](#pone.0236992.g002){ref-type="fig"}.

![Cellular ROS following INH exposure and scavenging effects of antioxidants.\
Cells were treated with or without 5μM INH for 24, 48 and 72 h. Data at 0 hour before INH treatment was also depicted in the figure. For control experiments the cells were not treated with INH. (A) ROS production was evaluated by flow cytometry using 2, 7-dichlorofluorescin-diacetate (DCF-DA) and we expressed the results in terms of % of cells having DCF fluorescence \[n = 5\]. (B) Levels of intracellular ROS in LX2 cells were measured by fluorescence spectrophotometry using 2,7-DCF-DA as the probe. We used arbitrary units of the fluorescence intensity per 10^6^ cells to assess the level of ROS \[n = 6\]. \*p\<0.05 compared to 0 h; \*\*p\<0.01 compared to previous time points. (C) 3 hours before treatment of INH, we treated LX2 cells in presence or absence of 10μM DPI or 2mM NAC, 0.2mM Tempol and 50μM CMZ. Using flow cytometry with 2, 7-dichlorofluorescin-diacetate as the probe, determination of ROS generation was done. We expressed the results in terms of % of cells having DCF fluorescence \[n = 5\]. \*p\<0.001 compared to control cells and \*\*p\<0.001 compared to INH treated group.](pone.0236992.g002){#pone.0236992.g002}

GSH level and antioxidant enzymatic activity in LX2 cells during INH treatment {#sec023}
------------------------------------------------------------------------------

GSH and other cellular antioxidant enzymes like GPx and catalase directly react with intracellular ROS produced by any source. We evaluated intracellular GSH level in LX2 cells at different time points of INH treatment. Cellular GSH level was comparable between control and INH treated LX2 cell line till 48 hours \[[Table 1](#pone.0236992.t001){ref-type="table"}\]. But at 72 hours, cellular GSH level was significantly decreased in INH treated LX2 cells (49.28 ± 4.40 nmole/mg of protein) compared to control cells (61.53 ± 6.82 nmole/mg of protein) p\<0.01 \[[Table 1](#pone.0236992.t001){ref-type="table"}\]. Intracellular catalase activity exhibited no significant changes between control and INH treated LX2 cells. Activity of cellular GPx was comparable between control and INH treatment till 48 hours as depicted in [Table 1](#pone.0236992.t001){ref-type="table"}. At 72 hours, activity of GPx was significantly increased in INH treated cells (102.63 ± 3.36 U/mg protein/min) compared to control cells (64.64 ± 1.53 U/mg protein/min) p\<0.001 \[[Table 1](#pone.0236992.t001){ref-type="table"}\].

10.1371/journal.pone.0236992.t001

###### Antioxidant status and lipid peroxidation products in LX2 cell line during INH treatment.

![](pone.0236992.t001){#pone.0236992.t001g}

  Parameters                                            24 Hours      P Value       48 Hours   PValue         72 Hours       PValue                                 
  ----------------------------------------------------- ------------- ------------- ---------- -------------- -------------- -------- -------------- -------------- ----------
  GSH (nmole/mg protein)                                60.40 ±4.47   61.12 ±2.35   ns         61.13 ± 6.08   59.68 ±5.23    ns       61.53 ± 6.82   49.28 ±4.40    p\<0.01
  GPx (μmole NADPH oxidized/min/mg protein)             63.81 ±3.67   64.92 ±7.09   ns         68.83 ± 5.78   72.88 ± 6.65   ns       64.64 ±1.53    102.63 ±3.36   p\<0.001
  Catalase (μmole H~2~O~2~ decomposed/min/mg protein)   5.67 ±1.45    5.73 ±0.67    ns         5.54 ± 0.91    5.87 ±0.71     ns       5.54 ±0.95     6.70 ±1.24     ns
  TBARs (nmole MDA formed/mg protein)                   0.55 ±0.03    0.54 ±0.21    ns         0.54 ± 0.06    0.61 ± 0.07    ns       0.54 ± 0.08    0.94 ±0.05     p\<0.001

GSH, reduced glutathione; GPx, glutathione peroxidase; TBARS, thiobarbituric acid reactive substances; MDA, malondialdehyde. Results are expressed as mean ± SD; n = 5.

Lipid peroxidation in LX2 cells during INH treatment {#sec024}
----------------------------------------------------

Lipid peroxidation products act as inducer of HSC activation. Therefore it was of interest to study the level of lipid peroxidation in LX2 cells during INH treatment. There was no difference in the products of lipid peroxidation between INH treated and control cells till 48 hours. However, at 72 hours 1.8 fold increase of malondialdehyde (MDA) level was detected in INH treated LX2 cells compared to control cells \[[Table 1](#pone.0236992.t001){ref-type="table"}\].

ROS and lipid peroxidation products are important mediators of stellate cell activation. Activation and perpetuation of HSCs are key steps in the development of hepatic fibrosis. We checked the expression markers of HSC activation in LX2 cells with or without INH treatment at different time intervals in both mRNA and protein level by RT-PCR and western blotting technique. After 72 hours of INH treatment to the LX2 cells, 2.1 fold increase of α-SMA mRNA expression was observed by real time PCR ([Fig 3A](#pone.0236992.g003){ref-type="fig"}), which was further confirmed by immunoblotting ([Fig 3B](#pone.0236992.g003){ref-type="fig"}). CYP2E1 inhibition by CMZ, repressed INH induced α-SMA expression in LX2 cells at 72 hours ([Fig 3C](#pone.0236992.g003){ref-type="fig"}). Expression of transforming growth factor beta (TGF-β), tissue inhibitors of metalloproteinase1 (TIMP1) and collagen1A1 (Col1A1) mRNA were less than 1.5 fold of the controls after 72 hours of INH treatment to LX2 cells ([Fig 3A](#pone.0236992.g003){ref-type="fig"}). Collagen is a major component of pathological extracellular matrix and HSCs secrete collagen upon its activation. We did not observe any collagen expression after 72 hours of INH treatment in LX2 cells neither in mRNA level nor in protein level. We also quantified total collagen released into the media using Sircol Collagen Assay kit but found no significant change in collagen level between control and INH treated LX2 cells ([Fig 3D](#pone.0236992.g003){ref-type="fig"}). Thus from these sets of data, we can predict that although INH can produce low level of ROS in HSCs, it does not activate HSCs to myofibroblasts and initiate collagenesis.

![The effect of INH on the activation of LX2 cells.\
(A) The mRNA expression levels of Col1A1, α-SMA, TGF-β and TIMP1 were evaluated in LX2 cells after 72 hours treatment with INH by real-time PCR. RT-PCR analysis revealed that the mRNA level of α-SMA was only up regulated by 2.1 fold compared to control, while mRNA levels of Col1A1, TGF-β and TIMP1 were not up regulated (less than 1.5 fold compared to control) by INH \[n = 6\]. (B) Western blot analysis of α-SMA after different hours of treatment with INH in LX2 cells. Data at 0 hour before INH treatment was also depicted in the figure. β-actin was used as the house keeping gene \[n = 5\]. (C) Effect of CMZ on activation of LX2 cells by INH by western blot of α-SMA at 72 hours. β-actin was used as the house keeping gene \[n = 5\]. (D) Effect of INH on total collagen content in LX2 cells was determined by Sircol collagen assay after different hours of treatment with INH \[n = 6\]. Data at 0 hour before INH treatment was also depicted in the figure.](pone.0236992.g003){#pone.0236992.g003}

Pyrazole enhances CYP2E1 activity in HSCs {#sec025}
-----------------------------------------

Pyrazole (PY) is known to elevate CYP2E1 activity in the liver by a post transcriptional mechanism stabilizing CYP2E1 against degradation \[[@pone.0236992.ref022]\]. In the present study, we pretreated the LX2 cells with PY (50 μM) to induce CYP2E1 in this cell line. Addition of INH in the PY pretreated LX2 cells caused more that 2 fold increase of CYP2E1 activity at 72 hours compared to INH treatment alone ([Fig 4A](#pone.0236992.g004){ref-type="fig"}). Parallel to increase of CYP2E1 activity, INH also increased NOX activity in PY pretreated LX2 cells (46.48 ± 3.97 μ moles/mg protein, p\<0.001 compared to only INH treatment (13.73 ± 1.27 μ moles/mg protein). NOX activity was found to be related with CYP2E1 activity (r = 0.93; p \<0.001) in LX2 cells ([Fig 4B](#pone.0236992.g004){ref-type="fig"}). Further western blot analysis also revealed that PY pretreated INH exposed LX2 cells have higher CYP2E1 expression at 72 hours ([Fig 4D](#pone.0236992.g004){ref-type="fig"}). NOX serves as the primary source of ROS in HSCs. In HSCs, NOX1 is always present. We did not observe NOX4 expression in control LX2 cells or at different hours of INH treatment in PY pretreated LX2 cells ([Fig 4D](#pone.0236992.g004){ref-type="fig"}). By western blot analysis, NOX1 and NOX2 were found to be the predominant subunits detected in LX2 cells during the INH treatment in PY pretreated cells, however the phagocytic NOX2 was progressively increased in PY pretreated LX2 cells during INH treatment ([Fig 4D](#pone.0236992.g004){ref-type="fig"}).

![The effect of pyrazole on CYP2E1 and NOX activity in LX2 cells.\
Specific activity of CYP2E1 in different treatment group such as control, INH, PY, INH treatment in PY pretreated cells was determined \[n = 6\]. \*p\<0.01 compared to control cells and \*\*p\<0.001 compared to INH treated group. (B) Correlation between NOX and CYP2E1 activity in LX2 cells during INH in presence and absence of CYP2E1 inducer PY \[n = 6\]. (C) Levels of intracellular ROS in LX2 cells were measured by fluorescence spectrophotometry using 2,7-DCF-DA as the probe. We expressed the results in terms of arbitrary units of the fluorescence intensity per 10^6^ cells in control, INH, PY and INH treatment in PY pre-treatment groups \[n = 6\]. \*p\<0.05 compared to INH treated group; \*\*p\<0.01 compared to INH treated group and \#p\<0.001 compared to INH+PY treated cells of previous time points. (D) Western blot analysis of CYP2E1, α-SMA, collagen1A1, NOX1, NOX2 and NOX4 in control, INH and INH plus PY treated LX2 cells at 72 hours. PY was added in the culture 3 hours before addition of INH in the medium \[n = 5\]. β-actin was used as in house control.](pone.0236992.g004){#pone.0236992.g004}

Pyrazole enhances INH induced oxidative stress {#sec026}
----------------------------------------------

As depicted in [Fig 4C](#pone.0236992.g004){ref-type="fig"}, in the PY pretreated INH group, intracellular ROS was rapidly increased compared to INH as well as PY groups. At 72 hours, GSH level in LX2 cells remained unchanged after PY exposure (62.33 ± 5.83 nmole/mg protein) compared to control cells (61.53 ± 6.82 nmole/mg protein). But INH exposure in PY pretreated cells caused significant depletion of GSH (38.28 ± 6.43 nmole/mg protein; p \<0.05) compared to INH treated group (49.28 ± 4.40). Further, the level of cellular lipid peroxidation in INH exposure in PY pretreated LX2 cells was also significantly increased (1.96 ± 0.29 nmole MDA formed/mg protein, p \<0.001) compared to only INH treated LX2 cells for 72 hours (0.94 ± 0.05 nmole MDA formed/mg protein). These data indicated development of more oxidative stress in PY pretreated LX2 cells during INH treatment.

Effect of INH, PY and INH plus PY on proliferation of LX2 cells {#sec027}
---------------------------------------------------------------

INH significantly increased LX2 proliferation following 72 hours of exposure as compared to control. More pronounced increase in proliferation was observed in PY pretreated INH group. Proliferation in LX2 cells was found to be markedly elevated after 72 hours of INH treatment (0.112 ± 0.005; p\<0.001) compared to control cells (0.062 ± 0.004). PY pretreated INH group exhibited further increase in cellular proliferation (0.259 ± 0.01; p\<0.001) as compared to only PY treated group (0.085 ± 0.004).

INH activates pyrazole pretreated LX2 cells {#sec028}
-------------------------------------------

The data of elevated CYP2E1 activity associated with increased intracellular ROS generation and evidence of increased oxidative stress in INH plus PY treated LX2 cells attempted us to evaluate activation of LX2 cells that can produce collagen 1 which is a major component of pathological extracellular matrix. So we studied α-SMA and COL1A1 mRNA level which was found to be elevated in PY pretreated LX2 cells during culture in INH treatment ([Table 2](#pone.0236992.t002){ref-type="table"}). The expression of profibrotic genes (e.g. TGFβ1 and TIMP-1) in the PY pretreated LX2 cells were also significantly increased by INH treatment ([Table 2](#pone.0236992.t002){ref-type="table"}). On the other hand, expression of both MMP-2 nd MMP-9 were significantly reduced in INH+PY treated group ([Table 2](#pone.0236992.t002){ref-type="table"}). In contrast, LX2 cells when cultured without INH (control cells) or only PY treatment for 72 hours did not cause expression of α-SMA, COL1A1 and profibrotic genes. Western blotting further confirmed over expression of α-SMA and collagen 1 in PY pretreated LX2 cells by INH at 72 hours ([Fig 4D](#pone.0236992.g004){ref-type="fig"}).

10.1371/journal.pone.0236992.t002

###### Increased expression of profibrotic genes (Fold induction against control) in LX2 cells at 72 hours of INH treatment in presence and absence of CYP2E1 inducer PY.

![](pone.0236992.t002){#pone.0236992.t002g}

  Genes          Folds increase                               
  -------------- ---------------- ------------- ------------- -------------------------------------------
  α-SMA          2.16 ± 0.61      1.52 ± 0.31   4.42 ± 0.15   [\*\*](#t002fn003){ref-type="table-fn"}
  TGF-β          1.38 ± 0.28      1.20 ± 0.16   3.16 ± 1.06   [\*](#t002fn002){ref-type="table-fn"}
  TIMP-1         1.28 ± 0.16      1.20 ± 0.12   2.28 ± 0.69   [\*](#t002fn002){ref-type="table-fn"}
  Collagen 1A1   1.18 ± 0.20      1.14 ± 0.17   2.82 ± 0.49   [\*\*](#t002fn003){ref-type="table-fn"}
  MMP-2          1.11 ± 0.08      1.07 ± 0.08   0.82 ± 0.07   [\*\*\*](#t002fn004){ref-type="table-fn"}
  MMP-9          1.07 ± 0.08      1.07 ± 0.11   0.77 ± 0.06   [\*\*\*](#t002fn004){ref-type="table-fn"}

α-SMA, alpha smooth muscle actin; TGF-β, transforming growth factor beta; TIMP-1, tissue inhibitors of metalloproteinase 1; MMP, matrix metalloproteinase. Results are expressed as mean ± SD; n = 5

\*p\<0.01 when compared with other groups

\*\*p\<0.001 when compared with other groups

\*\*\*p\<0.05 when compared with INH group.

Discussion {#sec029}
==========

We could demonstrate in the above experiments that preconditioning and collateral help by a CYP2E1 activation status modifier PY augments the ability of INH to establish a full blown profibrogenic milieu and lead to activation of collagen deposition. The sequential and graded increase of oxidative stress, HSC activation but not collagen mRNA expression by INH alone followed by a demonstration that augmentation by PY pretreatment could provide this final push is very much consonant with the pathogenesis of clinical ATD induced hepatotoxicity happening mostly with combination therapy. Fibrosis evolve more indolently than acute events and it would be important to know that INH alone is insufficient to trigger for that.

In this study we showed low level of CYP2E1 as well as intracellular ROS production following INH treatment. This low level of ROS was not able to enhance COL1A1 mRNA expression and increase collagen production. INH caused increased collagen synthesis in LX2 cells when CYP2E1 was induced in this cell line by pretreatment with PY.

CYP2E1 is involved in the activation of a number of compounds to reactive intermediates that produce tissue damage \[[@pone.0236992.ref023]--[@pone.0236992.ref025]\]. CYP2E1 is an active producer of ROS, which are generated from its catalytic cycle even in the absence of substrate \[[@pone.0236992.ref024], [@pone.0236992.ref025]\]. In liver, apart from hepatocytes being the primary source of CYP2E1, Kupffer cells also exhibited significant amounts of CYP2E1 \[[@pone.0236992.ref026]\]. But discordant reports on the CYP2E1 level in the HSC are available. According to Yamada et al, presence of CYP2E1 was maximum in the rat hepatocytes and the CYP2E1 level in rat HSC was 21% of the rat hepatocytes \[[@pone.0236992.ref027]\]. CYP2E1 protein expression in HSC was about 4% of the hepatocytes as observed by Oinonen et al \[[@pone.0236992.ref028]\]. CYP2E1 was not found to be expressed in human HSCs as reported by Casini et al \[[@pone.0236992.ref029]\]. CYP2E1 level was found to get elevated in liver by INH as documented from previous study \[[@pone.0236992.ref030]\]. In the present study, no immunoreactive CYP2E1 protein was detected in LX2 cells under basal conditions but low activity of CYP2E1 was observed. INH exposure caused slow elevation of CYP2E1 activity associated with mild intracellular ROS formation and lipid peroxidation products accumulation in LX2 cells in response to INH exposure, but the concentrations of ROS and products of lipid peroxidation are not sufficient to elicit effects on HSC activation and enhance collagen synthesis. As PY is a CYP2E1 inducer, we induced CYP2E1 level at basal condition in the LX2 cell by pretreatment with PY to examine whether INH could be bio activated rapidly in LX2 cells and increase cellular ROS production, develop oxidative stress and enhance collagen expression. We could confirm that INH can enhance collagen expression if the intracellular CYP2E1 levels in HSC remain high. High level of CYP2E1 in HSC was associated with increased cellular stress and lipid peroxidation products in response to INH exposure.

ROS are found to be one of the crucial players of stellate cell activation. Apart from the amount of ROS produced, the level of antioxidants also plays a potential role in modulating HSC activation. Oxidative stress is a phenomenal event due to excess accumulation of ROS along with severe loss of antioxidant levels. In chronic liver disease, marked depletion of antioxidant levels occur in liver. In stellate cells also depletion of antioxidants is observed which could further amplify the process of fibrogenesis \[[@pone.0236992.ref031]\]. This study showed evidence that in PY pretreated LX2 cells, the increased expression of CYP2E1 by INH was associated with increased production of ROS, GSH depletion, altered antioxidants status, and expression of collagen.

Since CYP2E1 perform an essential role in DILI apart from fatty liver disorder and alcoholic liver damage, the mechanism behind regulation of CYP2E1 induction needs further investigation. A variety of exogenous substrates as well as endogenous substrates induce CYP2E1 expression that further trigger damage to hepatocytes via generation of ROS and products of lipid peroxidation. However, there is lack of experimental evidences indicating the direct involvement of the CYP2E1 inducer in the activation of HSCs.

The strength in our study is in the robustness and the novelty of the data sets, in-vitro designs pursued to address the primary question of activation of HSC and fibrogenesis during INH exposure by CYP2E1 inducer. Further in presence of CYP2E1 inducer PY, we demonstrate with precision the relevant pathophysiological changes in a sequential manner beginning with progressive development of intracellular ROS, loss of cellular antioxidants, activation of HSCs and increase collagen synthesis during INH treatment. We believe this to be the first detailed functional description of increase collagen synthesis during INH treatment in presence of CYP2E1 inducer and the connotations of the findings are fairly wide particularly in patients having alcohol abuse, intake of high fat diet and concomitant use of drugs.

In conclusion, we have been able to demonstrate that INH can lead to HSC activation directly resulting in increased collagen synthesis in the presence of CYP2E1 inducer. Our study provides initial experimental evidence to a simmering body of clinical data suggesting that drugs to be important agents in chronic hepatitis, particularly in presence of CYP2E1 inducer.

Supporting information {#sec030}
======================

###### 

(PDF)

###### 

Click here for additional data file.
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To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Partha Mukhopadhyay, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

3\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.

4\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes
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2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes
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3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have achieved substantially in investigating the underlying mechanism of isoniazid (INH)-dependent hepatocyte stellate cell (HSC) activation. The manuscript is structured well and proceeds smoothly with a logical flow. However, the manuscript presents certain fundamental flaws addressing which will improve the manuscript considerably.

Major

• The authors need to have every detail of the reagents and chemicals used in each experiment mentioned in the manuscript. Various sub-sections of the "materials and methods" section (cell line and culture, treatment of cells, and induction of CYP2E1) lack relevant details including catalog numbers and vendors for the reagents used in this study. I will suggest that the authors incorporate the information in the sub-sections mentioned above. Moreover, the authors will need to include the information on the respective primary antibody dilutions in the "western blotting" sub-section too.

• In the "biochemical assays" sub-section of the "materials and methods," the authors do not elaborate on the technique used to measure the reduced intracellular glutathione (GSH), thiobarbituric acid reactive substances (TBARs), and protein content. Providing at least a brief overview of the technique is necessary, in addition to the provided references. Similarly, I would like to point to the absence of a detailed explanation of the assay technique used for measuring the activities of CYP2E1, catalase, glutathione peroxidase (GPx), and NADPH oxidase (NOX). Since determining the activities of these proteins are a crucial part of the presented data, it is of great importance that the authors explain the activity assay used for this study.

• The authors have performed the Sircol Collagen Assay (line 255) and presented the result in Figure 3C. There is, however, no mention of the assay technique in the "materials and methods" section. I want to emphasize that every experimental procedure should be documented with enough details for any researcher to reproduce it if needed. I will suggest the authors to provide the catalog number and vendor as well.

Minor

• Some of the paragraphs or portions of paragraphs are underlined within the manuscript. Is it done deliberately, what does it mean? I will suggest that the authors be consistent in their manuscript preparation.

• The authors indicate in the "statistical analysis" that all the experiments have were replicated at least five times (line 147). None of the individual figures possess any information on the number of replicates used for each experiment (Figures 1 through 4). I will suggest that the authors provide the exact number of experimental replicates used to prepare the quantification graphs in each figure.

Reviewer \#2: English writing in the manuscript need to be improved.

Question 1:

In Figure 1D, the expression of NOX was detected by western blot. What are the NOX1 (T) and NOX1 (C)? The results and figure legend didn't explain these items.

The results need to show the expression of NOX in untreated cells. After INH treatment, there is not the obvious increase in NOX1 expression between 24h and 72h. But, due to the lack of the results in untreated cells, I didn't know the change in NOX1 expression after INH treatment compare to the untreated control.

Question 2:

In Figure 4A, the results showed the CYP2E1 activity was increased after INH, PY or INH+PY treatment. Could the authors also show the results using western blot about the expression of CYP2E1 after INH, PY or INH+PY treatment?

Question 3:

CYP2E1 is expressed mainly in hepatocytes and generates reactive oxygen species (ROS). Accumulation of reactive oxygen species (ROS) serves as a driving force for HSC activation. HSC cells expressed very low level CYP2E1. After INH 72 h treatment, the CYP2E1 expression is slightly increased in HSC cells. The increased CYP2E1 after INH treatment could not increase the collagen synthesis. In order to increase the expression of CYP2E1 in HSC cells, the author used pyrazole (PY) pre-treated HSC cells to increase the expression of CYP2E1. Since Hepatocytes can express the high level CYP2E1, Why the authors mimic the in vivo environment to use co-cultured transwell method to investigate whether INH-induced CYP2E1 expression in hepatocytes affect the HSC activation in vitro culture assay?

Question 4:

The results showed INH or PY+INH treatment can induce HSC activation. Upon activation, HSCs express a combination of MMPs and TIMPs to remodel the ECM and facilitate the progression of liver fibrosis. How about the proliferation of HSC cells and MMP expression after INH or PY+INH treatment?

Question 5:

In Figure 2C, the results showed pretreatment of LX2 cells with anti-oxidants or NOX inhibitor can reduce the intracellular ROS formation in response to INH treatment. How about the effect of CYP2E1 inhibitor in the same experiment?

Since the authors demonstrated that INH-induced CYP2E1 expression can activate HSC cells, Whether the CYP2E1 inhibitor can reverse the effect in response to INH treatment?

\*\*\*\*\*\*\*\*\*\*
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Response to Reviewers

We would like to thank the academic editor and the reviewers for critical review of our manuscript and for their thoughtful comments and constructive suggestions, which help to improve the quality of this manuscript. Point wise answer of additional requirements and the comments of the reviewers are follows:

Response in relation of additional requirements:

"Please ensure that your manuscript meets PLOS ONE's style requirements, including those for the naming"

Answer: We have carefully revised our manuscript as per format of PLOS ONE style.

　　2. "ORCID ID of the corresponding author"

Answer: The ORCID ID of the corresponding author, Dr. Abhijit Chowdhury, is [orcid.org/0000-0001-9198-4436](http://orcid.org/0000-0001-9198-4436).

"PLOS ONE requires the authors provide the original uncropped and unadjusted images underlying blots or gel results reported in a submission's figures or supporting information files"

Answer: Original uncropped and unadjusted images are submitted in a separate file "S1_raw_images" as per suggestion.

　　We are really sorry for not providing all the uncropped and unadjusted images of blots for Figure 1D. Dr. Suman Santra left the department to join his Post Doctoral research program in USA and Dr. Amal Santra on superannuation of his service at IPGME&R, Kolkata, left the department and joined at JCM Center for Liver research and Innovation Kolkata. His lab at IPGME&R was shifted to JCM Center for Liver Research and innovation, Kolkata. During shifting his lab, some of the documents were misplaced and missing. This is the reason; we are unable to submit the uncropped and unadjusted images of blots of NOX1 (T) and NOX2 for figure 1D. Hope, the academic editor as well as the reviewers will sympathetically consider our case.

　　Further, in our lab, we carried out western blot development protocol using the sensitive chemiluminescent substrate (Supersignal west Pico plus chemiluminescent reagent (34580; Thermo Scientific, U.S.A) for the detection of horseradish peroxidase (HRP) exposed to X-ray film. For gel electrophoresis and western blot, we used Thermo Scientific SpectraTM Multicolor Broad Range Protein Ladder (26634) which is a prestained protein ladder. This is a ready to use ladder which can be directly loaded into gels. Since it is a prestained protein ladder, we couldnt visualize any signal for the protein marker lane after development protocol onto the exposed Xray film except for our desired protein of interest.

"We noted that you have included the phrase "Data not shown" included in your manuscript. Unfortunately this does not meet the journal's data sharing requirements. PLOS ONE does not permit references to inaccessible data."

Answer: Our previous statement "Data not Shown" is corrected properly in the revised manuscript.

　　Response of the comments of Reviewer 1:

　　Major comments:

"The authors need to have every details of the reagents and chemicals used in each experiment in the manuscripts. ........ Moreover, the need to include the information on the respective primary antibody dilution in the Western blotting sub-section too".

Answer: As per suggestion of the reviewer, details of the reagents and chemicals are provided in the revised manuscript along with catalogue numbers and vendors. Moreover, dilutions of the primary antibodies are mentioned in the revised text.

"In the biochemical assays sub-section of the materials and methods, The authors do not elaborate on the technique used to use different parameters like GSH, TBARS, protein content, CYP2E1, GPx, NOX"

Answer: As per suggestion of the reviewer, we elaborate all the biochemical techniques used in the revised text.

The authors have performed the Sircol Collagen assay and presented in the result. However, there is no mention of the assay technique in the materials and methods section".

Answer: Sircol Collagen assay technique is mentioned in the materials and methods section in the revised text.

Minor comments:

"Some of the paragraphs or portions of paragraphs are underlined within the manuscript. Is it done deliberately, what does it mean? I will suggest that the authors be consistent in their manuscript".

Answer: Necessary changes are made in the revised manuscript as per suggestion of the reviewer.

The authors indicate in the statistical analysis that all the experiments have were replicated at least five times. None of the individual figures possess any information on the number of replicates used for each experiment. I will suggest that the authors provide the exact number of experimental replicated used to prepare the quantification graphs in each figure".

Answer: Number of times the experiments were conducted is inserted within the figure legends.

　　Response of the comments of Reviewer 2:

Question 1: "In figure 1D, the expression of NOX was detected by western blot. What are NOX1 (T) and NOX1 (C)? The results and figure legend didn't explain these items.

The results need to show the expression of NOX in untreated cells. After INH treatment, there is not the obvious increase in NOX1 expression between 24 and 72 h. But due to lack of results in the untreated cells, I didn't know the change in NOX1 expression after INH treatment compared to untreated control".

Answer: In figure 1D, NOX1 (C) and NOX1 (T) are explained in the figure legends. NOX1 (C) is untreated control and NOX1 (T) is INH treated cells. After treatment of INH, increase of NOX1 expression between 24 and 72 hours exhibited no change. There is no difference in expression of NOX1 between control \[NOX1 (C)\] and INH treated cells \[NOX1 (T)\].

Question 2: In Figure 4A, the results showed the CYP2E1 activity was increased after INH, PY or INH+PY treatment. Could the authors also show the results using western blot about the expression of CYP2E1 after INH, PY or INH+PY treatment?

Answer: As per suggestion of the reviewer, expression of CYP2E1 by western blot after INH, PY and INH+PY treatment is provided in the text and in figure 4D.

Question 3: CYP2E1 is expressed mainly in hepatocytes and generate ROS. Accumulation of ROS serves as a driving force for HSC. ...............the authors used pyrazole (PY) pre-treated HSC to increase the expression of CYP2E1. ... affect the HSC activation in vitro culture assay.

Answer: Since it is a short term study, to enhance CYP2E1 activity in LX2 cells, we have used PY to induce CYP2E1.

Question 4: The results showed INH or PY treatment can induce HSC activation. Upon activation HSCs express a combination of MMPs and TIMPs to remodel the ECM and facilitate the progression of liver fibrosis. How about the proliferation of HSC and MMP expression after INH or INH+PY treatment?

Answer: As per suggestion of the reviewer, proliferation of HSC cells after INH or PY+INH treatment is inserted within the revised text. Further, results of MMP 2 amd MMP 9 are also provided in Table 2 as well as in the text.

Question 5: In figure 2C, the results showed pretreatment of LX2 cells with anti-oxidant or NOX inhibitor can reduce the intracellular ROS formation in response to INH treatment. How about the effect of CYP2E1 inhibitor in the same experiment?

Since the authors demonstrated that INH induced CYP2E1 expression can activate HSC, whether the CYP2E1 inhibitor can reverse the effect in response to INH treatment?

Answer: ROS generation in presence of CYP2E1 inhibitor was significantly reduced which is provided in the text and figure 2C.

Activation of LX2 cells in presence of CYP2E1 inhibitor was markedly reduced which is provided in the text and figure 3C.
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Dear Dr. Chowdhury,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

One of the reviewer raised a minor comments which need to be addressed. 

Please submit your revised manuscript by Jul 19 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Partha Mukhopadhyay, Ph.D.

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: In Fig1, Fig2A and Fig3B and 3D, the authors should present the data at 0 hours before INH treatment.

The author mentioned that INH treatment only induce low level CYP2E1 expression in Line 448. The authors used PY as a chemical inducer to induce the CYP2E1 expression. The expression of CYP2E1 induced by PY has no obvious difference compared to the INH treatment in Fig 4. Why the PY as a chemical inducer of CYP2E1 alone could not significantly increase the CYP2E1 level compared to the INH treatment? Only INH+PY treatment can significantly increase the CYP2E1 level compare to the INH treatment alone?

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

11 Jul 2020

Response to Reviewers

We would like to thank the academic editor and the reviewer for critical review of our manuscript and for their thoughtful comments and constructive suggestions, which help to improve further the quality of this manuscript. Point wise answers of the comments of the reviewer are follows:

　　Response of the comments of Reviewer 2:

Question 1: "In Fig1, Fig2A and Fig3B and 3D, the authors should present the data at 0 hours before INH treatment".

Answer: As per suggestion of the reviewer, we have included the data at 0 hours before INH treatment in Fig 1; Fig 2A and Fig 3B and 3D in our revised version of the manuscript.

Question 2: "The author mentioned that INH treatment only induce low level CYP2E1 expression in Line 448. The authors used PY as a chemical inducer to induce the CYP2E1 expression. The expression of CYP2E1 induced by PY has no obvious difference compared to the INH treatment in Fig 4. Why the PY as a chemical inducer of CYP2E1 alone could not significantly increase the CYP2E1 level compared to the INH treatment? Only INH+PY treatment can significantly increase the CYP2E1 level compare to the INH treatment alone?"

Answer: In our study, we used a single dose of CYP2E1 inducer pyrazol (PY) at a lower dose to examine any synergistic effect of CYP2E1 expression in PY pre-treated LX2 cells, during INH treatment. Using a dose of 50 µM of PY alone, expression of CYP2E1 expression in LX2 cells was comparable to INH treatment. At this level of CYP2E1 expression in LX2 cells, the increased oxidative stress developed in the cells could not produce collagen 1 which is a major pathological extracellular matrix. Treatment of INH in PY pre-treated LX2 cells, produce synergistic effect on CYP2E1 induction in LX2 cells, resulting increased CYP2E1 mediated increased oxidative stress, activation of LX2 cells that can produce collagen 1.
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Click here for additional data file.
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PONE-D-19-35497R2

Dear Dr. Chowdhury,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.Congratulation for the great work!

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Partha Mukhopadhyay, Ph.D.

Section Editor

PLOS ONE
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Expression of type I collagen in response to Isoniazid exposure is indirect and is facilitated by collateral induction of Cytochrome P450 2E1: An in-vitro study

Dear Dr. Chowdhury:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Partha Mukhopadhyay

Section Editor

PLOS ONE
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